Vutrisiran Market 2026 reaching $1.18 billion by 2030 at a CAGR of 12%

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Vutrisiran Market During The Forecast Period 2026–2030?

The market for vutrisiran has experienced significant expansion recently. Forecasts indicate this market is set to increase from $0.67 billion in 2025 to $0.75 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.1%. Historically, this expansion has been driven by factors such as breakthrough siRNA approvals, the addressing of unmet needs in hATTR amyloidosis, the drawbacks of liver transplant alternatives, the broadening of orphan drug policies, and advancements in genetic diagnosis.

The vutrisiran market size is projected to experience substantial expansion in the coming years. By 2030, its valuation is anticipated to reach $1.18 billion, exhibiting a compound annual growth rate (CAGR) of 12.0%. This projected growth during the forecast timeframe stems from factors such as increasing awareness of rare diseases, an expanding pipeline of RNA therapeutics, the growing uptake of long-acting treatments, enhanced genetic screening practices, and the proliferation of specialty care facilities. Key trends identified for the forecast period encompass the increasing acceptance of RNA interference therapies, a heightened emphasis on rare genetic disorders, the development of treatments with extended dosing intervals, a surging demand for targeted amyloidosis treatments, and greater utilization of subcutaneous RNA medications.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21320&type=smp

What Underlying Factors Are Accelerating The Growth Of The Vutrisiran Market?

Future expansion of the vutrisiran market is anticipated to be driven by rising investments in research and development. Research and development (R&D) involves systematic investigation and experimentation aimed at creating new products, services, or processes, or enhancing existing ones. This surge in R&D funding stems from government programs and financial support, increasing demands in healthcare and pharmaceuticals, and broader concerns for sustainability and the environment. Financial backing for R&D enables pharmaceutical firms to carry out clinical trials, which prove the drug’s safety and enduring advantages, thus facilitating wider regulatory endorsements. Furthermore, progress in RNA interference (RNAi) technology enhances the drug’s accuracy, minimizing adverse effects and boosting patient acceptance. A notable example is data from the UK’s Office for National Statistics (April 2025), indicating that the UK government’s net expenditure on R&D climbed to approximately US $22.9 billion (£17.4 billion) in 2023, an increase from about US $20.0 billion (£16.1 billion) in 2022. Consequently, heightened investment in research and development is propelling the expansion of the vutrisiran.

What Market Segments Are Evaluated Within The Vutrisiran Market?

The vutrisiran market covered in this report is segmented –

1) By Drug Class: RNA Interference (RNAi) Therapeutics, GalNAc-Conjugated Nucleic Acid Drugs, Synthetic RNA-Based Therapeutics

2) By Route Of Administration: Injectable, Subcutaneous

3) By Patient Demographics: Adult, Geriatric

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By RNA Interference (RNAi) Therapeutics: Small Interfering RNA (siRNA) Drugs, Gene-Silencing RNA Therapies

2) By GalNAc-Conjugated Nucleic Acid Drugs: GalNAc-Conjugated siRNA Therapies, Hepatocyte-Targeted RNA Therapeutics

3) By Synthetic RNA-Based Therapeutics: Chemically Modified RNA Therapeutics, Long-Acting RNA Therapeutics

What Industry Trends Are Redefining The Vutrisiran Market?

Leading firms operating in the vutrisiran market are extending its application to cardiomyopathy through regulatory clearances, for example, a supplemental indication for ATTR CM, aiming to widen the patient demographic and enhance enduring value. An sNDA, or supplemental new drug application, represents a regulatory submission designed to broaden an approved medication’s scope to include additional indications. Illustratively, in March 2025, the US-based biotech firm Alnylam Pharmaceuticals secured FDA approval for AMVUTTRA (vutrisiran) for adult patients suffering from transthyretin amyloidosis cardiomyopathy (ATTR-CM), marking it as the inaugural RNAi therapeutic sanctioned for both the polyneuropathy and cardiomyopathy manifestations of the condition. Consequently, this expansion into cardiomyopathy stands as a pivotal trend propelling growth within the vutrisiran market by enhancing its clinical applicability and improving patient accessibility.

Who Are The Top Market Participants Influencing The Vutrisiran Market?

Major companies operating in the vutrisiran market are Alnylam Pharmaceuticals Inc

Read the full vutrisiran market report here:

https://www.thebusinessresearchcompany.com/report/vutrisiran-global-market-report

Which Region Is Projected To Dominate The Vutrisiran Market During The Forecast Period?

North America was the largest region in the vutrisiran market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vutrisiran market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Vutrisiran Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21320&type=smp

Browse Through More Reports Similar to the Global Vutrisiran Market 2026, By The Business Research Company

Vulvodynia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/vulvodynia-treatment-global-market-report

Vasopressin Market Report 2026

https://www.thebusinessresearchcompany.com/report/vasopressin-global-market-report

Vasodilators Market Report 2026

https://www.thebusinessresearchcompany.com/report/vasodilators-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795